Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2014

Open Access 01-12-2014 | Research article

Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

Authors: Yasuji Inamo, Katsuya Saito, Maki Hasegawa, Rika Hayashi, Takahiro Nakamura, Osamu Abe, Teruaki Ishikawa, Yayoi Yoshino, Koji Hashimoto, Tatsuo Fuchigami

Published in: BMC Pediatrics | Issue 1/2014

Login to get access

Abstract

Background

Dalteparin, a low-molecular-weight heparin, has anticoagulant and anti-angiogenic activity. This study investigated whether dalteparin reduced coronary artery lesion (CAL) prevalence, and resistance to intravenous immunoglobulin (IVIG) therapy in Kawasaki disease (KD).

Methods

This retrospective study comprised two parts. In the first cohort, 126 patients with KD (68 male, 58 female; median age: 22 months, range: 1–67 months) admitted to Nihon University Nerima-Hikarigaoka Hospital from January 2004 to June 2008, received either dalteparin 75 IU/kg/day, IVIG 400 mg/kg/day for 5 consecutive days, and aspirin 30 mg/kg/day, or dalteparin 75 IU/kg/day and aspirin 30 mg/kg/day, until clinical improvement. Control data came from the 2005–6 Nationwide KD survey. In the second cohort, 112 patients with KD (59 male, 53 female; median age: 19 months, range: 1–66 months) admitted from June 2010 to February 2012, received either dalteparin 75 IU/kg/day, IVIG 2.0 g/kg over 12 h, and aspirin 30 mg/kg/day, or dalteparin 75 IU/kg/day and aspirin 30 mg/kg/day. Control data came from the 2009–10 Nationwide KD survey. No patients enrolled in the nationwide surveys received dalteparin. All patients at our institution were given dalteparin in their combination therapy.

Results

A comparison of the first cohort with controls in the nationwide survey showed that the prevalence of initial administration of IVIG was 80.2% versus 86.0%; the rate of additional IVIG administration was 7.1% versus 14.0% (p = 0.03); CAL prevalence in the acute period was 4.8% versus 11.9% (p < 0.01); and the prevalence of cardiovascular sequelae was 0% versus 3.8% (p < 0.05). A comparison of the second cohort with controls in the nationwide survey showed that the rate of initial administration of IVIG was 92.9% versus 89.5%; the rate of additional IVIG administration was 8.9% versus 17.1% (p = 0.02); the prevalence of resistance to IVIG was 3.6% versus 14.9% (p < 0.001); and CAL prevalence in the acute period was 2.7% versus 8.6% (p = 0.03).

Conclusions

This study found that adjunctive dalteparin was associated with a lower prevalence of IVIG resistance and CAL in young children with KD.

Trial registration

UMIN-CTR: UMIN000010349.
Appendix
Available only for authorised users
Literature
1.
Durongpisitkul K, Gururaj VJ, Park JM, Martin CF: The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995, 96 (6): 1057-1061.PubMed
2.
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, et al: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991, 324 (23): 1633-1639. 10.1056/NEJM199106063242305.CrossRefPubMed
3.
Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, Kotani K, Tsogzolbaatar EO, Yanagawa H: Epidemiologic features of Kawasaki disease in Japan: results of the 2009–2010 nationwide survey. J Epidemiol. 2012, 22 (3): 216-221.CrossRefPubMedPubMedCentral
4.
Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, Newburger JW: Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009, 124 (1): 1-8. 10.1542/peds.2008-0730.CrossRefPubMed
5.
Breunis WB, Davila S, Shimizu C, Oharaseki T, Takahashi K, van Houdt M, Khor CC, Wright VJ, Levin M, Burns JC, et al: Disruption of vascular homeostasis in patients with Kawasaki disease: involvement of vascular endothelial growth factor and angiopoietins. Arthritis Rheum. 2012, 64 (1): 306-315. 10.1002/art.33316.CrossRefPubMed
6.
Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y: Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol. 1999, 83 (3): 337-339. 10.1016/S0002-9149(98)00864-9.CrossRefPubMed
7.
Ebata R, Abe J, Yasukawa K, Hamada H, Higashi K, Suwazono Y, Saito H, Terai M, Kohno Y: Increased production of vascular endothelial growth factor-d and lymphangiogenesis in acute Kawasaki disease. Circ J. 2011, 75 (6): 1455-1462. 10.1253/circj.CJ-10-0897.CrossRefPubMed
8.
Takeshita S, Kawamura Y, Takabayashi H, Yoshida N, Nonoyama S: Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clin Exp Immunol. 2005, 139 (3): 575-579. 10.1111/j.1365-2249.2005.02714.x.CrossRefPubMedPubMedCentral
9.
Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, Rowley AH: Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation. 2002, 105 (6): 766-769. 10.1161/hc0602.103396.CrossRefPubMed
10.
Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008, 121 (5): 637-645. 10.1016/j.thromres.2007.06.015.CrossRefPubMed
11.
Norrby K, Nordenhem A: Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. Apmis. 2010, 118 (12): 949-957. 10.1111/j.1600-0463.2010.02635.x.CrossRefPubMedPubMedCentral
12.
Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005, 146 (3): 333-343. 10.1038/sj.bjp.0706344.CrossRefPubMedPubMedCentral
13.
Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M: Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)–a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res. 1993, 72 (6): 475-500. 10.1016/0049-3848(93)90109-2.CrossRefPubMed
14.
Manlhiot C, Brandao LR, Somji Z, Chesney AL, MacDonald C, Gurofsky RC, Sabharwal T, Chahal N, McCrindle BW: Long-term anticoagulation in Kawasaki disease: initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities. Pediatr Cardiol. 2010, 31 (6): 834-842. 10.1007/s00246-010-9715-8.CrossRefPubMed
15.
Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, Ishii M, Harada K: Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005, 47 (2): 232-234. 10.1111/j.1442-200x.2005.02033.x.CrossRefPubMed
16.
Harada K: Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn. 1991, 33 (6): 805-810. 10.1111/j.1442-200X.1991.tb02612.x.CrossRefPubMed
17.
Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H: Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005–2006. J Epidemiol. 2008, 18 (4): 167-172. 10.2188/jea.JE2008001.CrossRefPubMedPubMedCentral
18.
Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)--digest version. Circ J. 2010, 74 (9): 1989-2020. 10.1253/circj.CJ-10-74-0903.
19.
Bratincsak A, Reddy VD, Purohit PJ, Tremoulet AH, Molkara DP, Frazer JR, Dyar D, Bush RA, Sim JY, Sang N, et al: Coronary artery dilation in acute Kawasaki disease and acute illnesses associated with Fever. Pediatr Infect Dis J. 2012, 31 (9): 924-926. 10.1097/INF.0b013e31826252b3.CrossRefPubMed
20.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, et al: Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012, 379 (9826): 1613-1620. 10.1016/S0140-6736(11)61930-2.CrossRefPubMed
21.
Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, et al: Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study. Circulation. 2011, 124 (25): 2822-2828. 10.1161/CIRCULATIONAHA.111.028423.CrossRefPubMed
22.
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, et al: Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008, 153 (6): 833-838. 10.1016/j.jpeds.2008.06.011.CrossRefPubMedPubMedCentral
Metadata
Title
Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study
Authors
Yasuji Inamo
Katsuya Saito
Maki Hasegawa
Rika Hayashi
Takahiro Nakamura
Osamu Abe
Teruaki Ishikawa
Yayoi Yoshino
Koji Hashimoto
Tatsuo Fuchigami
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2014
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/1471-2431-14-27

Other articles of this Issue 1/2014

BMC Pediatrics 1/2014 Go to the issue

Research article

Calprotectin in Cystic Fibrosis

Research article

Reduced crying in term infants fed high beta-palmitate formula: a double-blind randomized clinical trial

Research article

Is parenting style a predictor of suicide attempts in a representative sample of adolescents?

Study protocol

Minimally invasive, imaging guided virtual autopsy compared to conventional autopsy in foetal, newborn and infant cases: study protocol for the paediatric virtual autopsy trial

Study protocol

Piccolipiù, a multicenter birth cohort in Italy: protocol of the study

Research article

Newborn care in Indonesia, Lao People’s Democratic Republic and the Philippines: a comprehensive needs assessment